Search
romiplostim (AMG531, Nplate)
Indications:
- chronic immune thrombocytopenic purpura
Dosage: 1-7 ug/kg SQ weekly
Adverse effects:
- does not appear to increase the risk of progression from myelodysplastic syndrome to acute myeloid leukemia [3]
Mechanism of action:
- small peptide that activates the megakaryocyte thrombopoietin receptor & stimulates platelet production
General
thrombopoietin receptor agonist
growth factor
References
- Kuter DJ et al,
Efficacy of romiplostim in patients with chronic immune
thrombocytopenic purpura: A double-blind randomised controlled
trial.
Lancet 2008, 371:395
PMID: 18242413
- Kuter DJ et al.
Romiplostim or standard of care in patients with immune
thrombocytopenia.
N Engl J Med 2010 Nov 11; 363:1889.
PMID: 21067381
- George JN.
Management of immune thrombocytopenia - Something old,
something new.
N Engl J Med 2010 Nov 11; 363:1959.
PMID: 21067388
- Boggs W
Romiplostim Not Tied to Leukemic Progression in Myelodysplastic
Syndromes
Medscape - Feb 01, 2018
https://www.medscape.com/viewarticle/892138